Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. (TNYA) priced its initial public offering on Jul 30, 2021 at $15.00 per share, within its $14.00–$16.00 range, raising $180M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $589.9M. Morgan Stanley was lead-left underwriter, joined by TD Cowen, Piper Sandler and Chardan. Wilson Sonsini advised the company and Davis Polk advised the underwriters.

Tenaya Therapeutics, Inc. is a biotechnology company developing curative therapies aimed at the underlying drivers of heart disease. Its pipeline targets defined patient sub-populations with both rare and highly prevalent forms of heart disease.

Status

IPO

Ticker

TNYA

Exchange

Nasdaq Global Select

Priced

Jul 30, 2021

IPO price

$15.00

Price range

$14.00–$16.00

Raised

$180M

Market cap at IPO price

$589.9M

First filed

Jul 9, 2021

Underwriters

Morgan Stanley, TD Cowen, Piper Sandler and Chardan

Company counsel

Wilson Sonsini

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.